[Lonazolac-Ca-a non-steroidal antirheumatic agent. Long-term clinical study in chronic polyarthritis].

Abstract

During a controlled open long-term study, Lonazolac-Ca, a new nonsteroidal antiphlogistic substance, has been tested in 35 patients with rheumatoid arthritis (stage I-III, according to Steinbrocker). The patients took 600 mg Lonazolac-Ca daily in three equal doses. The observation period was one year. Clinical and laboratory controls were carried out in monthly intervals. In more than 50% of the patients the tested parameters pain, swelling and active mobility improved significantly. Because of acute deterioration of the basic disease which necessitated the application of steroids, therapy with Lonazolac-Ca was discontinued in some cases. Lonazolac-Ca is well tolerated. But also as with other non-steroidal antiphlogistics, administration of the substance may be restricted in individual cases due to gastric symptoms. No adverse effect on blood count, liver and kidney function was seen.

• Authors: G Lonauer, H Wagner, U Boerngen, K M Goebel
• Journal: Zeitschrift fur Rheumatologie (Z Rheumatol) 1981 Jul-Aug Vol. 40 Issue 4 Pg. 161-4 ISSN: 0340-1855 [Print] Germany
• Vernacular Title: Lonazolac-Ca - ein nicht steroidales Antirheumatikum. Klinische Langzeitstudie bei chronischer Polyarthritis.
• PMID: 7027681 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Acetates
• Anti-Inflammatory Agents
• Pyrazoles
• lonazolac

Topics

• Acetates (adverse effects, therapeutic use)
• Adult
• Aged
• Anti-Inflammatory Agents
• Arthritis, Rheumatoid (drug therapy)
• Clinical Trials as Topic
• Female
• Humans
• Male
• Middle Aged
• Nausea (chemically induced)
• Pyrazoles (adverse effects, therapeutic use)